A Novel and Rapid Method to Quantify Treg Mediated Suppression of CD4 T Cells

Overview

Journal J Immunol Methods

Publisher Elsevier

Specialties Allergy & Immunology
Pathology

Date 2017 Jun 27

PMID 28648384

Citations 10

Authors

Anna E Long

Megan Tatum

Carmen Mikacenic

Jane H Buckner

Affiliations

Soon will be listed here.

Abstract

Measuring regulatory T cell suppression provides important insight into T cell dysfunction in autoimmune disease. However, to date, suppression assays are limited by the requirement for freshly isolated cells, and significant cell numbers. Here, we present a novel and rapid in vitro assay using effector T cell surface expression of both CD25 and CD134 as a surrogate marker of regulatory T cell-mediated suppression. This surface marker-based suppression assay works for frozen samples and for samples with limited cell numbers. It is also shorter taking two days to complete compared to the four days required for proliferation-based assays. Furthermore, this assay works with both in vitro expanded and natural Tregs, as well as anti-CD3/anti-CD28 bead-based and APC stimulation conditions. In conclusion, we have developed and validated a new suppression assay for cryopreserved samples with limited cell numbers that may be helpful to investigate T cell regulation in the context of infection or autoimmune diseases.

Citing Articles

Single cell suppression profiling of human regulatory T cells.

Sondergaard J, Tulyeu J, Priest D, Sakaguchi S, Wing J Nat Commun. 2025; 16(1):1325.

PMID: 39900891 PMC: 11791207. DOI: 10.1038/s41467-024-55746-1.

Regulatory T cells suppress CD4+ effector T cell activation by controlling protein synthesis.

So L, Obata-Ninomiya K, Hu A, Muir V, Takamori A, Song J J Exp Med. 2023; 220(3).

PMID: 36598533 PMC: 9827529. DOI: 10.1084/jem.20221676.

IL-6-targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function.

Speake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort M JCI Insight. 2022; 7(22).

PMID: 36282595 PMC: 9746808. DOI: 10.1172/jci.insight.159436.

Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint.

Lutter L, Van Der Wal M, Brand E, Maschmeyer P, Vastert S, Mashreghi M Clin Transl Immunology. 2022; 11(10):e1420.

PMID: 36204213 PMC: 9525321. DOI: 10.1002/cti2.1420.

IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.

Greenbaum C, Serti E, Lambert K, Weiner L, Kanaparthi S, Lord S JCI Insight. 2021; 6(21).

PMID: 34747368 PMC: 8663550. DOI: 10.1172/jci.insight.150074.

References

Tohma S, Ramberg J, Lipsky P . Expression and distribution of CD11a/CD18 and CD54 during human T cell-B cell interactions. J Leukoc Biol. 1992; 52(1):97-103. DOI: 10.1002/jlb.52.1.97. View

Ruitenberg J, Boyce C, Hingorani R, Putnam A, Ghanekar S . Rapid assessment of in vitro expanded human regulatory T cell function. J Immunol Methods. 2011; 372(1-2):95-106. DOI: 10.1016/j.jim.2011.07.001. View

Kim H, Imbert J, Leonard W . Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 2006; 17(5):349-66. DOI: 10.1016/j.cytogfr.2006.07.003. View

Mikacenic C, Schneider A, Radella F, Buckner J, Wurfel M . Cutting edge: Genetic variation in TLR1 is associated with Pam3CSK4-induced effector T cell resistance to regulatory T cell suppression. J Immunol. 2014; 193(12):5786-90. PMC: 4258445. DOI: 10.4049/jimmunol.1401185. View

Zaunders J, Munier M, Seddiki N, Pett S, Ip S, Bailey M . High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol. 2009; 183(4):2827-36. DOI: 10.4049/jimmunol.0803548. View

Croft M, So T, Duan W, Soroosh P . The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009; 229(1):173-91. PMC: 2729757. DOI: 10.1111/j.1600-065X.2009.00766.x. View

Goodman W, Levine A, Massari J, Sugiyama H, McCormick T, Cooper K . IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol. 2009; 183(5):3170-6. PMC: 2903207. DOI: 10.4049/jimmunol.0803721. View

Mardiney 3rd M, Brown M, Fleisher T . Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. Cytometry. 1996; 26(4):305-10. DOI: 10.1002/(SICI)1097-0320(19961215)26:4<305::AID-CYTO11>3.0.CO;2-V. View

Wang M, Windgassen D, Papoutsakis E . Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics. 2008; 9:225. PMC: 2396644. DOI: 10.1186/1471-2164-9-225. View

10.

Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E . CD40/CD40L signaling and its implication in health and disease. Biofactors. 2009; 35(6):474-83. DOI: 10.1002/biof.62. View

11.

Wells A, Gudmundsdottir H, Turka L . Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest. 1998; 100(12):3173-83. PMC: 508531. DOI: 10.1172/JCI119873. View

12.

Bacchetta R, Passerini L, Gambineri E, Dai M, Allan S, Perroni L . Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest. 2006; 116(6):1713-22. PMC: 1472239. DOI: 10.1172/JCI25112. View

13.

Berglund D, Karlsson M, Biglarnia A, Lorant T, Tufveson G, Korsgren O . Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials. Clin Exp Immunol. 2013; 173(2):310-22. PMC: 3722931. DOI: 10.1111/cei.12112. View

14.

McMurchy A, Levings M . Suppression assays with human T regulatory cells: a technical guide. Eur J Immunol. 2011; 42(1):27-34. DOI: 10.1002/eji.201141651. View

15.

Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner J . The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol. 2008; 181(10):7350-5. PMC: 2597079. DOI: 10.4049/jimmunol.181.10.7350. View

16.

Endl J, Rosinger S, Schwarz B, Friedrich S, Rothe G, Karges W . Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes. 2005; 55(1):50-60. View

17.

Hannon M, Lechanteur C, Lucas S, Somja J, Seidel L, Belle L . Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion. 2013; 54(2):353-63. DOI: 10.1111/trf.12279. View

18.

Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R . Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol. 2011; 85(21):11422-34. PMC: 3194952. DOI: 10.1128/JVI.05608-11. View

19.

Lawson J, Tremble J, Dayan C, Beyan H, Leslie R, Peakman M . Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin Exp Immunol. 2008; 154(3):353-9. PMC: 2633239. DOI: 10.1111/j.1365-2249.2008.03810.x. View

20.

Putnam A, Brusko T, Lee M, Liu W, Szot G, Ghosh T . Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2008; 58(3):652-62. PMC: 2646064. DOI: 10.2337/db08-1168. View